Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study

References

• Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–338. ​​​​​
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273–281.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP task force on cancer pain. International Association for the Study of Pain. Pain. 1999;82(3):263–274.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(1–2):129–134.
   PubMed Web of Science ®Google Scholar
• Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20(2):87–92.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18(3):177–183.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag. 2010;6(2):97–108.
   PubMedGoogle Scholar
• Williams JE, Yen JT, Parker G, et al. Prevalence of pain in head and neck cancer out-patients. J Laryngol Otol. 2010;124(7):767–773.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Bertetto O, Labianca R, et al. Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI—Italian questionnaire for intense episodic pain. J Pain Symptom Manage. 2012;43(5):833–841.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006;7(8):583–591.
   PubMed Web of Science ®Google Scholar
• Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat Med. 2001;15(3):243–246.
   PubMed Web of Science ®Google Scholar
• Narayana A, Katz N, Shillington AC, et al. National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes. Pain. 2015;156(2):252–259.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Lazzari M, Reale C, et al. Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settings. Clin J Pain. 2015;31(3):214–221.
   PubMed Web of Science ®Google Scholar
• Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013;46(5):619–628.
   PubMed Web of Science ®Google Scholar
• Zeppetella G. Breakthrough pain in cancer patients. Clin Oncol (R Coll Radiol). 2011;23(6):393–398.
   PubMed Web of Science ®Google Scholar
• Elsner F, Zeppetella G, Porta-Sales J, et al. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Clin Drug Investig. 2011;31(9):605–618.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68.
   PubMed Web of Science ®Google Scholar
• Simon SM, Schwartzberg LS. A review of rapid-onset opioids for breakthrough pain in patients with cancer. J Opioid Manag. 2014;10(3):207–215.
   PubMedGoogle Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91(1–2):123–130.
   PubMed Web of Science ®Google Scholar
• Webster LR, Slevin KA, Narayana A, et al. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med. 2013;14(9):1332–1345.
   PubMed Web of Science ®Google Scholar
• Ashburn M, Slevin KA, Messina J, et al. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg. 2011;112(3):693–702.
   PubMed Web of Science ®Google Scholar
• Montague L, Green CR. Cancer and breakthrough pain’s impact on a diverse population. Pain Med. 2009;10(3):549–561.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag. 2010;6(2):109–116.
   PubMedGoogle Scholar
• Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15(7):756–763.
   PubMed Web of Science ®Google Scholar
• Bedard G, Hawley P, Zhang L, et al. A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer. 2013;21(9):2557–2563.
   PubMed Web of Science ®Google Scholar
• Raj SX, Thronaes M, Brunelli C, et al. A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. Support Care Cancer. 2014;22(7):1965–1971.
   PubMed Web of Science ®Google Scholar
• Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38–44.
   PubMed Web of Science ®Google Scholar
• Twomey F, O’Brien T, O’Reilly M, et al. An observational research study to evaluate the impact of breakthrough cancer pain on the daily lives and functional status of patients. Ir Med J. 2015;108(6):174–176.
   PubMedGoogle Scholar
• Brief pain inventory (short form): MD Anderson Cancer Center. 1991 [updated 2013 Sep 24; cited 2016 Oct 31]. Available from: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/bpisf.pdf
   Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89–95.
   PubMed Web of Science ®Google Scholar
• Ware J Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
   PubMed Web of Science ®Google Scholar
• Lowe B, Decker O, Muller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008;46(3):266–274.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–1292.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Barber C, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45(2):156–174.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Ames M, Hymel PA, et al. Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med. 2004;46(6 Suppl):S23–S37.
   PubMed Web of Science ®Google Scholar
• Ware JE Jr., Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33(4 Suppl):AS264–AS279.
   PubMed Web of Science ®Google Scholar
• Kongsgaard UE, Eeg M, Greisen H. The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study. Support Care Cancer. 2014;22(6):1655–1662.
   PubMed Web of Science ®Google Scholar
• Vellucci R, Fanelli G, Pannuti R, et al. What to do, and what not to do, when diagnosing and treating breakthrough cancer pain (BTcP): expert opinion. Drugs. 2016;76(3):315–330.
   PubMed Web of Science ®Google Scholar
• Katz N. Coxibs: evolving role in pain management. Semin Arthritis Rheum. 2002;32(3 Suppl 1):15–24.
   PubMed Web of Science ®Google Scholar
• Novotna S, Valentova K, Fricova J, et al. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Clin Ther. 2014;36(3):357–367.
   PubMed Web of Science ®Google Scholar
• Davies A, Kleeberg UR, Jarosz J, et al. Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. Support Care Cancer. 2015;23(7):2135–2143.
   PubMed Web of Science ®Google Scholar